Ryan Coleman

Depressive Symptom Severity in Patients with Major Depressive Disorder (MDD) at Study Exit in the One-Year SHORELINE Study of Episodic Treatment with Zuranolone

Abstract: Introduction Zuranolone is an investigational neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an o...

Andrew Czysz ;

Ryan Coleman ;

01/19/2023

Safety and Efficacy of Zuranolone 50 mg and Need for Repeat Treatment Courses in the Open-label, Phase 3 SHORELINE Study of Adult Patients With Major Depressive Disorder

Abstract: Introduction Zuranolone is a neuroactive steroid and positive allosteric modulator of both synaptic and extrasynaptic GABAA receptors in clinical development as an oral, once-da...

Andrew J. Cutler , MD;

Ryan Coleman ;

01/19/2023

Assessing the Need for Repeat Treatment Courses with Zuranolone in Adult Patients With Major Depressive Disorder With Elevated Anxiety: An Analysis of the Open-Label, Phase 3 SHORELINE Study

Abstract: Introduction Zuranolone is an investigational neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an o...

Greg Mattingly , MD;

Ryan Coleman ;

01/19/2023